Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases 2025 Annual Meeting
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease Liver Meeting 2025
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Sankamap Secures Two-Year Prospecting Licence Renewals for District-Scale Kuma and Fauro Copper Gold Properties
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT
